?? Congratulations to CSL for the approval of their ?????????? ???????????????????? ???????????????? Andembry (garadacimab) in Australia! Andembry is now approved for the prevention of recurrent hereditary angioedema (HAE) attacks. Andembry is a novel Factor XIIa-inhibitory monoclonal antibody (anti-FXIIa mAb) to treat HAE, a form of bradykinin-mediated angioedema. It inhibits the plasma protein factor XIIa, which when activated, initiates the cascade of events leading to oedema (swelling) at various sites of the body. Read the press release here: https://lnkd.in/e26Asv8H #Biointron #Antibodies #PharmaNews #DrugApproval #Monoclonal
